[이데일리 김새미 기자] HLB (028300) announced on the 17th that its U.S. subsidiary Eleva has acquired the global rights (excluding Korea and China) for ‘Camrelizumab’, an immunotherapy drug being developed by China’s Hengshe Pharmaceutical as a liver cancer treatment. From the left, Eleva CEO Jeong Se-ho and Jin Yang-gon Chairman of HLB Group, Shun Piaoyang, Chairman of Hengshe Pharmaceutical, and Frank Jiang, Chief Strategy Officer of Hengshe Pharmaceutical (Photo = HLB) Under this contract, Hengshe Pharmaceutical will receive up to $1 billion on a cumulative basis depending on the sales volume in the liver cancer field for 10 years after the start of sales of camrelizumab. You will receive a royalty of (approximately KRW 1.3 trillion). HLB and Elevar have secured global rights to the company’s targeted anti-cancer drug ‘Riboceranib’, which succeeded in phase 3 global liver cancer clinical trials, as well as global rights in the liver cancer field to the immuno-anticancer drug ‘Camrelizumab’, a combination drug.
This was decided at a strategic level to maximize competitiveness in the first-line liver cancer treatment field in the United States. Eleva plans to maximize sales by conducting the commercialization process, including marketing and sales, of the two drugs prescribed together after approval as liver cancer treatments.
As a result, HLB believes that it has gained momentum to secure global partnerships and begin early sales of liver cancer treatments, which are expected to be approved for new drugs in the first half of next year. Jeong Se-ho, CEO of Eleva, explained, “The fact that the concomitant drugs are products of different companies could have been a weakness in marketing,” and “By overcoming this, commercialization can proceed more quickly and efficiently.”
On July 14, Eleva received approval for NDA filing from the U.S. Food and Drug Administration (FDA) and received drug sales licenses in 15 U.S. states. This decision makes it possible to establish joint marketing and sales networks for the two drugs targeting major cancer hospitals in the United States. As a result, the company expects that synergies will increase, such as strengthening awareness, encouraging prescriptions, and reducing costs.
Jin Yang-gon, Chairman of HLB Group, said, “In order to gain a clear competitive advantage in the first-line liver cancer treatment market, we judged that it was essential for one company to have authority over both drugs and conduct marketing.” He added, “Sales of two liver cancer treatments “As we have secured leadership, we will stand tall as the best-in-class anticancer drug in the liver cancer field,” he emphasized.
Meanwhile, HLB and Eleva plan to attend the European Society for Cancer Research (ESMO 2023), which will be held for four days starting on the 20th, to discuss strategies for establishing a European approval and sales network for liver cancer treatments with foreign pharmaceutical companies. The results of the first global phase 3 clinical trial for liver cancer using rivoceranib and camrelizumab in combination were published in The Lancet, the world’s most prestigious medical science journal, in July.
2023-10-17 01:25:43
#HLB #acquires #global #distribution #rights #Hengseo #Pharmaceuticals #Camrelizumab #liver #cancer